Clinical Trial Update: Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL [Phase 1]

View source ↗

Summary

A Phase 1 trial of the GTL001 vaccine with imiquimod adjuvant in HPV 16/18-infected women aged 25–65 with normal cytology, ASCUS, or LSIL was terminated; the up…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• GTL001 (GTL001)
• Imiquimod Cream (Imiquimod)

Snippet

Sponsor: Genticel | Conditions: HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL | Phase 1 | Status: TERMINATED